RB1 and neoplasm: Conversely, trials investigating novel therapeutic approaches in the TP53/RB1-deficient phenotype should take into account that a proportion of genomic aberrations in TP53 and RB1 are not detected when assessing diagnostic treatment-naive primary tumor specimens.